Instrument Inactif

Autres langues Foamix Pharmaceuticals Ltd. Nasdaq

Actions

IL0011334385

Recherche biotechnologique et médicale

Autres langues

13/08	Yarrow Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
13/08	Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
12/08	RTW Biotech's Avere to go public in US in reverse merger with NextCure
29/07	RTW Biotech's Portfolio Company Completes Merger with Vyne Therapeutics
28/07	Yarrow Bioscience, Inc.(NasdaqCM:YARW) added to NASDAQ Composite Index
27/07	Yarrow Bioscience, Inc. completed the acquisition of VYNE Therapeutics Inc. from AI Biotechnology LLC, Nantahala Capital Management LLC, and other shareholders in a reverse merger transaction.
27/07	Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101
27/07	Yarrow Bioscience, Inc. announced that it has received $200 million in funding from a group of investors
24/07	Top Premarket Decliners
23/07	VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
21/07	VYNE Approves 1-for-50 Reverse Stock Split
21/07	VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
10/07	VYNE Therapeutics Inc. Declares Special Cash Dividend, Payable on July 23, 2026
10/07	VYNE Therapeutics Declares Estimated $0.38-Per-Share Special Cash Dividend Ahead of Yarrow Merger
10/07	VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
15/06	Yarrow Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
21/05	VYNE Therapeutics : Yarrow Bioscience Investor Presentation
15/05	VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
27/02	VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
18/12	RTW Biotech Opportunities announces new investment in Yarrow Bioscience
17/12	Yarrow Bioscience, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire VYNE Therapeutics Inc. in a reverse merger transaction.
17/12	Vyne Therapeutics and Yarrow Bioscience announce merger agreement
17/12	VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
17/12	Yarrow Bioscience, Inc. announced that it expects to receive $200 million in funding from a group of investors
06/11	VYNE Therapeutics Q3 net loss narrows, strategic review ongoing